Dipeptidyl peptidase IV inhibitors in diabetes: More than inhibition of glucagon-like peptide-1 metabolism?

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 377, Issue 3, 2008, Pages 205-207

  Michel, Martin C ^a   Fliers, Eric ^a   Van Noorden, Cornelis J F ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

CD26; Diabetes; Dipeptidyl peptidase IV; Glucagon like peptide 1; Peptide YY

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; INSULIN; PEPTIDE YY;

ENZYME BINDING; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; IMMUNITY; INSULIN RELEASE; METABOLIC INHIBITION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PROTEASE INHIBITORS;

EID: 42449140570     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-008-0280-0     Document Type: Review

References (23)

1. 3-36 physiologically inhibits food intake. Nature 418:650-654
2. 5 receptor subtype. Endocrinol 139:3018-3021
3. Boggiano MM, Chandler PC, Oswald KD, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Schindler M, Arndt K, Rudolf K, Mark M, Schoelch C, Joost HG, Klaus S, Thöne-Reineke C, Benoit SC, Seeley RJ, Beck-Sickinger AG, Koglin N, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Deng XY, Whitcomb DC, Halem H, Tayloer J, Dong J, Datta R, Culler M, Ortmann S, Castaneda TR, Tschöp M (2005) PYY3-36 as an anti-obesity drug target. Obesity Rev 6:307-322
4. Boonacker E, Van Noorden CJF (2003) The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 82:53-73
5. Combettes M, Kargar C (2008) Newly approved and promising antidiabetic agents. Therapie 62:293-310
6. 3-36 on food intake in humans. Gastroenterology 129:1430-1436
7. Hermansen K, Kipnes M, Luo E, Faurik D, Khatami H, Stein P (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, Obesity & Metab 9:733-745
8. 3-36 on feed intake and plasma acyl-ghrelin levels in pigs. J Endocrinol 191:113-119
9. Kikkawa F, Kajiyama H, Shibata K, Ino K, Nomura S, Mizutani S (2005) Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta 1751:45-51
10. 3-36-induced feeding reduction in rats. Endocrinol 146:2369-2375
11. Mentlein R, Dahms P, Grandt D, Krüger R (1993) Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49:133-144
12. Michel MC, Beck-Sickinger AG, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz TW, Westfall TC (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY and pancreatic polypeptide receptors. Pharmacol Rev 50:143-150
13. Ohnuma K, Inoue H, Uchiyama M, Yamochi T, Hosono O, Dang NH, Morimoto C (2006) T-cell activation via CD26 and caveolin-1 in rheumatoid synovium. Mod Rheumatol 16:3-13
14. 3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones. Am J Physiol (in press)
15. Reinhold D, Bank U, Täger M, Ansorge S, Wrenger S, Thielitz A, Lendeckel U, Faust J, Neubert K, Brocke S (2008) DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. Front Biosci 13:2356-2363
16. Reinhold D, Biton A, Goihl A, Pieper S, Lendeckel U, Faust J, Neubert K, Bank U, Täger M, Ansorge S, Brocke S (2007) Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses. Ann N Y Acad Sci 1110:402-409
17. 3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol 293:E604-E609
18. 3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol 292:E1062-E1068
19. Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M (2008) Pharmacological profile of ASP8497, a novel, selective and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn-Schmiedeberg's Arch Pharmacol (in press). DOI 10.1007/s00210-008-0277-8
20. Thielitz A, Ansorge S, Bank U, Tager M, Wrenger S, Gollnick H, Reinhold D (2008) The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin disease. Front Biosci 13:2364-2375
21. Thompson MA, Ohnuma K, Abe M, Morimoto C, Dang NH (2007) CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem 7:253-273
22. Utzschneider KM, Tong J, Montgomery B, Udaysankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan M, Foley JE, Holst JJ, Deacon CF, Kahn SE (2008) The dipeptidyl peptidase-4 inhibitor vildagliptin improves β-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31:108-113
23. 3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol 292:E238-E245